Trial Profile
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2025
Price :
$35
*
At a glance
- Drugs Aldoxorubicin (Primary) ; Avelumab (Primary) ; Brachyury peptide vaccine (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Docetaxel (Primary) ; ETBX 011 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; GI 4000 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors NantKwest
Most Recent Events
- 21 Feb 2025 Planned initiation date changed from 1 Sep 2018 to 1 Jun 2018.
- 21 Feb 2025 Planned primary completion date changed from 30 Dec 2019 to 1 Aug 2018.
- 23 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.